// Yu Liu 1,2 , Wen-zhu Wan 1 , Yan Li 1 , Guan-lian Zhou 1 and Xin-guang Liu 2 1 School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, Jinan, P. R. China 2 Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China Correspondence to: Xin-guang Liu, email: // Keywords : phosphatidylinostitol-3-kinase; PI3K; inhibitor; mTOR pathway; anticancer Received : August 15, 2016 Accepted : October 04, 2016 Published : October 18, 2016 Abstract Phosphatidylinostitol-3-kinase (PI3K) is the potential anticancer target in the PI3K/Akt/ mTOR pathway. Here we reviewed the ATP-competitive small molecule PI3K inhibitors in the past few years, including the pan Class I PI3K inhibitors, the isoform-specific PI3K inhibitors and/or the PI3K/mTOR dual inhibitors.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) studied this question.